Posted by Michael Wonder on 17 Aug 2021
FDA grants accelerated approval of Jemperli (dostarlimab-gxly) for dMMR recurrent or advanced solid tumours
17 August 2021 - Second FDA approval of PD-1 antagonist antibody under clinical development for solid tumours in collaboration with GSK.
AnaptysBio today announced that the U.S. FDA approved a second indication for GSK’s Jemperli (dostarlimab-gxly) for the treatment of adult patients with mismatch repair deficient recurrent or advanced solid tumours, as determined by an FDA approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.
